Skip to content

exosome-focused translational research for afatinib

exosome-focused translational research for afatinib - EXTRA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000024935
Enrollment
60
Registered
2017-01-01
Start date
2017-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Sponsors

Teikyo University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: non small cell lung cancer diagnosed adenocarcinoma having Ex19 mutation, Ex.21 mutation, uncommon mutation using afatinib as first line treatment ECOG PS 0,1 healthy patient It is expected to survive for at least 3 months. writing consent is obtained

Exclusion criteria

Exclusion criteria: Illegal disorders such as idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated synchronous or allochronic malignancies having the history of preoperative anticancer treatments

Design outcomes

Primary

MeasureTime frame
Identification of pharmacological markers and resistance factors of afatinib using exosome-derived molecules

Secondary

MeasureTime frame
Relationship between various factors and response rate, disease control ratio, progression-free survival time, overall survival time Consideration of compatibility of results between serum specimen and serum exosome specimen

Countries

Japan

Contacts

Public ContactNoriyuki Matsutani

Teikyo University School of Medicine Surgery

matsutan@med.teikyo-u.ac.jp03-3964-1231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026